




Commonwealth of Massachusetts
Executive Office of Health and Human Services
Office of Medicaid
www.mass.gov/masshealth

Managed Care Entity Bulletin 112

DATE: March 2024

TO: Managed Care Entities Participating in MassHealth

FROM: Mike Levine, Assistant Secretary for MassHealth 

RE: **Obesity Drugs and the 340B Drug Pricing Program Change in Effective Date**

Applicable Managed Care Entities and PACE Organizations

- ☒ Accountable Care Partnership Plans (ACPPs)
- ☒ Managed Care Organizations (MCOs)
- ☐ MassHealth's behavioral health vendor
- ☒ One Care Plans
- ☒ Senior Care Organizations (SCOs)
- ☐ Program of All-inclusive Care for the Elderly (PACE) Organizations

Summary

This bulletin relates to certain drugs that may be used for the treatment of obesity that a provider purchased through the 340B Drug Pricing Program (340B stock). The bulletin applies to Accountable Care Partnership Plans (ACPPs), Managed Care Organizations (MCOs), One Care Plans, and Senior Care Organizations (SCOs) (collectively referred to as "Managed Care Entities").

In [MCE Bulletin 109](#), the Executive Office of Health and Human Services (EOHHS) directed Managed Care Entities not to pay for specified GLP-1 agonist drugs if those drugs were purchased through the 340B Drug Pricing Program, effective April 1, 2024.

Through this Bulletin, EOHHS is delaying the effective date of this policy until July 1, 2024. EOHHS is making no other changes to the policy, which is described below.

Payment for GLP-1 Agonist Drugs That May Be Used in the Treatment of Obesity – Effective July 1, 2024

As described in [MCE Bulletin 109](#), Section 2.7.B.5.b of the First Amended and Restated Accountable Care Partnership Plan Contract for the MassHealth ACO Program and Section 2.7.B.5.b of the Sixth Amended and Restated MassHealth MCO Contract require the following of the ACPPs and MCOs:

With respect to drugs and drug classes specified by EOHHS, provide coverage in a manner that maximizes EOHHS's ability to collect drug rebates, including but not limited to excluding such drugs and drug classes from reimbursement through the Contractor's 340B program, as further specified by EOHHS.

Similar contract language will be added to the One Care and SCO contracts in upcoming amendments.

To maximize EOHHS's ability to collect drug rebates on the following drugs, EOHHS is directing Managed Care Entities to not pay for the following drugs if the provider uses 340B stock:

- Saxenda® (liraglutide)
- Victoza® (liraglutide)
- Ozempic® (semaglutide)
- Rybelsus® (semaglutide)
- Wegovy® (semaglutide)
- Mounjaro® (tirzepatide)*
- Zepbound® (tirzepatide)*

*Tirzepatide is a glucose-dependent insulintropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist.

Effective July 1, 2024, Managed Care Entities may pay for the drugs designated above only when providers use non-340B stock.

This policy applies only to MassHealth members. Managed Care Entities' provision of 340B stock for these drugs to individuals who are not MassHealth members is not affected by this bulletin.

MassHealth Website

This bulletin is available on the [MassHealth Provider Bulletins](#) web page.

[Sign up](#) to receive email alerts when MassHealth issues new bulletins and transmittal letters.

Questions

If you have questions about the information in this bulletin, please

- Contact the MassHealth Customer Service Center at (800) 841-2900, TDD/TTY: 711, or
- Email your inquiry to provider@masshealthquestions.com.

 [MassHealth on Facebook](#)  [MassHealth on X \(Twitter\)](#)  [MassHealth on YouTube](#)